Skip to main navigation

Investor Relations

September 24, 2020

ABIVAX presents first-half 2020 financial results and operations update

September 02, 2020

Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study

July 02, 2020

Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial

June 22, 2020

Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting

June 15, 2020

Abivax Receives € 5m Non-dilutive Financing from Société Générale as State Guaranteed Loan